pre-rRNA 2'-O-ribose RNA methyltransferase FTSJ3 (FTSJ3)

pre-rRNA 2'-O-ribose RNA methyltransferase FTSJ3 (FTSJ3) is an S-adenosylmethionine-dependent enzyme responsible for the 2'-O-methylation of ribosomal RNA, which is critical for proper ribosome biogenesis and function[1][3][10]. FTSJ3 has additional biological roles in the context of disease, notably promoting immune evasion in multiple cancers (including hepatocellular carcinoma) and being hijacked by certain viruses (such as HIV) to modify their RNA and escape innate immune detection[2][4][6]. Increased FTSJ3 activity is associated with tumor progression and reduced survival in cancer patients; its inhibition may synergize with immunotherapies targeting immune checkpoints such as PD-1[2]. Targets such as FTSJ3 that modify RNA and thus influence immune recognition represent emerging nodes for intervention in cancer and infectious disease therapy[2][4][6][10].

Other names

FTSJ3SB92SPB1FtsJ homolog 3FtsJ RNA methyltransferase homolog 3Putative rRNA methyltransferase 3SPB1 RNA methyltransferase homologEPCS3pre-rRNA 2'-O-ribose RNA methyltransferase FTSJ32'-O-ribose RNA methyltransferase SPB1 homologFtsJ RNA 2'-O-methyltransferase 3rRNA (uridine-2'-O-)-methyltransferase 3

Drugs or molecules targeting FTSJ3 may act by inhibiting its 2'-O-methyltransferase activity, thereby enhancing immune detection of dsRNA and promoting type I interferon responses or synergizing with checkpoint blockade therapies